arrow
A

Antoine Hollebecque

gustave roussy
H指数:65
被引数:2.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Development and external validation of a prognostic score associated with poor outcomes in patients receiving immune checkpoint blockade-containing therapies enrolled in early-phase clinical trials

基于早期临床试验中接受免疫检查点阻断治疗患者的预后评分的开发与外部验证:与不良结局相关的评分

2026-07-010
PRE
Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC)

性别在非小细胞肺癌(NSCLC)中对处于研发阶段的抗体药物偶联物(ADCs)耐受性的差异

2026-06-012
OAAI
Acute kidney injury in patients included in early-phase oncology clinical trials, results of the AKITEP study

早期肿瘤学临床试验纳入患者中的急性肾损伤,AKITEP研究的结果

2026-05-260
PRE
Lung-only metastatic pancreatic cancer: differences in patients ‘characteristics, molecular profile and survival

肺转移性胰腺癌:患者特征、分子谱和生存差异

2026-01-090
PRE
Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations

饱和诱变鉴定激活和抗性诱导FGFR激酶结构域突变

2025-12-080
OAAI
Efficacy and Safety of Olomorasib in Combination with Pembrolizumab in Treatment of Patients with KRAS G12C-Mutant Advanced NSCLC

奥罗莫西布与帕博利珠单抗联合治疗KRAS G12C突变型晚期非小细胞肺癌的疗效与安全性

2025-11-290
PRE
Comprehensive molecular landscape of anal squamous cell carcinoma: analysis of tissue and liquid biopsies from 1844 patients

肛门鳞状细胞癌的全面分子图谱:1844例患者的组织活检和液体活检分析

2025-11-240
OAAI
Single-cell Transcriptome Profiling of Post-treatment and Treatment-naïve Colorectal Cancer: Insights into Putative Mechanisms of Chemoresistance

治疗后与初治结直肠癌的单细胞转录组分析:化疗耐药潜在机制的见解

2025-11-090
PRE
Real-World Immunotherapy Outcomes in Unresectable Peritoneal Mesothelioma: A French Experience

不可切除性腹膜间皮瘤的真实世界免疫治疗效果:一项法国经验

2025-10-200
PRE
Multimodal Management of Retroperitoneal Lymph Node Metastases in Colorectal Cancer: A Single-Center Retrospective Analysis

结直肠癌腹膜后淋巴结转移的多模式管理:一项单中心回顾性分析

2025-10-140
PRE
Management of biliary tract cancers in elderly patients: a French multicenter retrospective study (PRONOBIL-ACABi)

老年患者胆道肿瘤的管理:一项法国多中心回顾性研究(PRONOBIL-ACABi)

2025-10-030
OA
Impact of oncology review meetings on second opinions for patients with gastrointestinal cancer

肿瘤学评审会议对胃肠道癌患者二次诊疗意见的影响

2025-09-200
PRE
ASO Visual Abstract: Multimodal Management of Retroperitoneal Lymph Node Metastases in Colorectal Cancer: A Single-Center Retrospective Analysis

ASO 视觉摘要:结直肠癌腹膜后淋巴结转移的多模式管理:一项单中心回顾性分析

2025-09-050
PRE
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma

I期ADP-A2AFP TCR T细胞疗法在晚期肝细胞癌或胃肝样腺癌患者中的临床试验

2025-08-120
PREAI
Young-Onset Biliary Tract Cancers: Characteristics, Treatment Patterns, and Patient Outcomes

早发型胆道系统癌症:特征、治疗模式及患者预后

2025-08-110
OAAI
Notch pathway inhibition with crenigacestat (LY3039478) in a phase I first-in-human clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia

使用crenigacestat(LY3039478)抑制Notch通路在复发或难治性非霍奇金淋巴瘤和B细胞慢性淋巴细胞白血病患者中的I期首次人体临床试验

2025-07-310
OA
Real-world efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient biliary tract cancer: An AGEO study

微卫星不稳定/错配修复缺陷型胆道癌中免疫检查点抑制剂的实时世界疗效:一项AGEO研究

2025-07-300
PRE